Ivacaftor can alleviate the symptoms of CF patients by improving the function of CFTR on the cell surface, enhancing the transport of chloride ions, increasing negative ion conductivity, improving mucus hydration, and decreasing mucus viscosity (Yu et al., 2012; Garg et al., 2019; Harbeson et al., 2017). The gene discussed is CFTR; the disease is cystic fibrosis.